Mrs. Amanda Leigh Lindsey, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 18060 County Road 331, Terrell, TX 75161 Phone: 214-773-4096 |
Melody Rene Julian, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 223 Willow Creek Ln, Terrell, TX 75160 Phone: 903-286-5759 |
Deborah Lee Bennett, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 201 Timber Ct Apt 112, Terrell, TX 75160 Phone: 608-566-4707 |
Mary Agyeiwaa Kwarteng, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 115 Redwood, Terrell, TX 75160 Phone: 972-563-3452 |
Jasmine Moire Brocker, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 10468 Estate Ln, Terrell, TX 75161 Phone: 903-340-5412 |
April Washburn, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 6188 County Road 125, Terrell, TX 75161 Phone: 972-978-0453 |
Mrs. Elizabeth Ann Shelton, BSN RN Registered Nurse - Wound Care Medicare: Not Enrolled in Medicare Practice Location: 15121 Saddle Ridge Cir, Terrell, TX 75160 Phone: 817-874-8222 |
Amber Nichole Martin, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 6275 Norton Dr, Terrell, TX 75160 Phone: 806-773-2329 |
Francisca Idemudia, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 134 Redwood, Terrell, TX 75160 Phone: 469-264-3664 |
Debra Anne Ofner, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 900 Morris St, Terrell, TX 75160 Phone: 214-417-4993 |
News Archive
For years, doctors have known that there is a link between childhood obesity and asthma, but have found it difficult to determine which condition tends to come first, or whether one causes the other.
Scientists at the University of Maryland School of Medicine have for the first time found direct causal links between the neurotransmitter dopamine and avoidance – behavior related to pain and fear.
Blueprint Medicines today announced that the U.S. Food and Drug Administration accepted the Company's Investigational New Drug (IND) applications to begin Phase 1 clinical trials for its two lead drug candidates: BLU-554 for the treatment of advanced hepatocellular carcinoma (HCC) and cholangiocarcinoma, and BLU-285 for unresectable, treatment-resistant gastrointestinal stromal tumor (GIST).
Generex Biotechnology Corporation today announced its receipt of a decision by the NASDAQ Listing Qualifications Panel, which granted the Company's request for continued listing of the Company's common stock on The NASDAQ Stock Market on an interim basis, subject to certain conditions subsequent which are described in the Form 8-K Current Report filed by the Company with the Securities and Exchange Commission on EDGAR earlier today.
› Verified 4 days ago